Breaking News, Collaborations & Alliances

Fresenius Kabi, TQ Therapeutics Partner to Advance CGT Accessibility

Under the agreement, TQ Therapeutics’ affinity and column-based cell isolation technology will be integrated into Fresenius Kabi’s Cue Cell Processing System.

Author Image

By: Charlie Sternberg

Associate Editor

Fresenius Kabi and TQ Therapeutics, have entered into a strategic-development agreement under which Fresenius Kabi has an exclusive license to develop, manufacture, and distribute products that incorporate TQ Therapeutics’ proprietary cell selection technology. The goal of the agreement is to advance cell and gene therapy accessibility by enabling scalable and efficient cell therapy manufacturing. Fresenius Kabi is a provider of essential medicines and medical technologies. TQ Therapeutics sp...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters